Health Canada has approved BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension), a once-yearly injectable treatment from Merck Animal Health. The product is indicated to provide 12 months of protection against fleas (Ctenocephalides felis) and several tick species, including Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), and Rhipicephalus sanguineus (brown dog tick). It is also indicated to control Amblyomma americanum (lone star tick) infestations for up to eight months in dogs six months of age and older.

“Though people often think of flea and tick season during the summer months, studies have shown that while fleas and ticks are most active from early spring through the fall, they can be active year-round in some areas, especially knowing it only takes a few warm days for ticks to become active,” says Frank Guerino, PhD, associate vice president of Global Pharmaceutical Development, Merck Animal Health.

Originally approved in Australia and New Zealand in 2023, BRAVECTO QUANTUM has since gained authorization in the European Union, the United States, and now Canada, with availability in more than 50 countries worldwide. For more information, visit the Merck Animal Health website.